

Grebinyk, Anna; Prylutska, Svitlana; Chepurna, Oksana; Grebinyk, Sergii;  
Prylutskyi, Yuriy; Ritter, Uwe; Ohulchanskyi, Tymish Y. ; Matyshevskaya, Olga;  
Dandekar, Thomas; Frohme, Marcus:

**Synergy of chemo- and photodynamic therapies with C<sub>60</sub> fullerene-doxorubicin nanocomplex**

---

*Original published in:* Nanomaterials : open access journal. - Basel : MDPI. - 9 (2019), 11, art. 1540, 19 pp.  
*Original published:* 2019-10-30  
*ISSN:* 2079-4991  
*DOI:* [10.3390/nano9111540](https://doi.org/10.3390/nano9111540)  
*[Visited:* 2019-11-13]



This work is licensed under a [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/). To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>



Article

# Synergy of Chemo- and Photodynamic Therapies with C<sub>60</sub> Fullerene-Doxorubicin Nanocomplex

Anna Grebinyk <sup>1,2</sup>, Svitlana Prylutska <sup>3</sup>, Oksana Chepurna <sup>4</sup>, Sergii Grebinyk <sup>1</sup>, Yuriy Prylutskyi <sup>3</sup>, Uwe Ritter <sup>5</sup>, Tymish Y. Ohulchanskyy <sup>4</sup>, Olga Matyshevskaya <sup>6</sup>, Thomas Dandekar <sup>2</sup> and Marcus Frohme <sup>1,\*</sup>

<sup>1</sup> Division Molecular Biotechnology and Functional Genomics, Technical University of Applied Sciences Wildau, Hochschulring 1, 15745 Wildau, Germany; grebinyk@th-wildau.de (A.G.); sgrebinyk@th-wildau.de (S.G.)

<sup>2</sup> Department of Bioinformatics, Biocenter, University of Würzburg, Am Hubland, 97074 Würzburg, Germany; dandekar@biozentrum.uni-wuerzburg.de

<sup>3</sup> Taras Shevchenko National University of Kyiv, Volodymyrska 64, 01601 Kyiv, Ukraine; psvit\_1977@ukr.net (S.P.); prylut@ukr.net (Y.P.)

<sup>4</sup> Key Laboratory of Optoelectronic Devices and Systems of Ministry of Education and Guangdong Province, College of Physics and Optoelectronic Engineering, Shenzhen University, Shenzhen 518060, China; ok.chepurna@gmail.com (O.C.); tyo@szu.edu.cn (T.Y.O.)

<sup>5</sup> Institute of Chemistry and Biotechnology, University of Technology Ilmenau, Weimarer Straße 25 (Curiebau), 98693 Ilmenau, Germany; uwe.ritter@tu-ilmenau.de

<sup>6</sup> Palladin Institute of Biochemistry, NAS of Ukraine, Leontovicha Str. 9, 01030 Kyiv, Ukraine; matysh@yahoo.com

\* Correspondence: mfrohme@th-wildau.de; Tel.: +49-(0)-3375-508-249

Received: 30 September 2019; Accepted: 27 October 2019; Published: 30 October 2019



**Abstract:** A nanosized drug complex was explored to improve the efficiency of cancer chemotherapy, complementing it with nanodelivery and photodynamic therapy. For this, nanomolar amounts of a non-covalent nanocomplex of Doxorubicin (Dox) with carbon nanoparticle C<sub>60</sub> fullerene (C<sub>60</sub>) were applied in 1:1 and 2:1 molar ratio, exploiting C<sub>60</sub> both as a drug-carrier and as a photosensitizer. The fluorescence microscopy analysis of human leukemic CCRF-CEM cells, in vitro cancer model, treated with nanocomplexes showed Dox's nuclear and C<sub>60</sub>'s extranuclear localization. It gave an opportunity to realize a double hit strategy against cancer cells based on Dox's antiproliferative activity and C<sub>60</sub>'s photoinduced pro-oxidant activity. When cells were treated with 2:1 C<sub>60</sub>-Dox and irradiated at 405 nm the high cytotoxicity of photo-irradiated C<sub>60</sub>-Dox enabled a nanomolar concentration of Dox and C<sub>60</sub> to efficiently kill cancer cells in vitro. The high pro-oxidant and pro-apoptotic efficiency decreased IC<sub>50</sub> 16, 9 and 7 × 10<sup>3</sup>-fold, if compared with the action of Dox, non-irradiated nanocomplex, and C<sub>60</sub>'s photodynamic effect, correspondingly. Hereafter, a strong synergy of therapy arising from the combination of C<sub>60</sub>-mediated Dox delivery and C<sub>60</sub> photoexcitation was revealed. Our data indicate that a combination of chemo- and photodynamic therapies with C<sub>60</sub>-Dox nanoformulation provides a promising synergetic approach for cancer treatment.

**Keywords:** photodynamic chemotherapy; synergistic effect; C<sub>60</sub> fullerene; Doxorubicin; nanocomplex; leukemic cells; apoptosis

## 1. Introduction

Chemotherapy (CT) as one of the conventional cancer therapies aims to slow down the growth of cancer cells that evolved in a fast proliferation [1]. The frontline anthracycline chemotherapeutic drug Doxorubicin (here abbreviated consistently Dox) intercalates into nuclear DNA initiating the

suppression of topoisomerase activity as well as of DNA transcription, replication, and repair [2–4]. Dox also affects the redox balance inducing reactive oxygen species (ROS) generation through metal chelation and flavoprotein reductase-associated redox cycling [4,5]. The extended ROS generation causes serious cardiotoxicity owing to the high content of mitochondria in cardiomyocytes [2,3,6] and limits the drug's clinical application.

The multimodal combination of therapies with distinct anticancer mechanisms offers potential advantages and enhanced efficiency compared to monotherapy approaches [7,8]. Photodynamic chemotherapy exploits two anticancer agents—a photosensitizing molecule and a chemotherapeutic drug [9–16]. The former is harmless itself but on illumination with visible light in the presence of oxygen induces cell death through ROS-mediated compact apoptosis [17,18]. Once combined, photodynamic therapy (PDT) and CT confront cancer cells with two different “swords”, resulting in a stronger therapeutic potential in comparison with the corresponding therapies apart or their theoretical sum. The advantageous synergistic effect is primarily attributed to the heterogeneity of cancer cell resistance to each of the monotherapies and finally aims to apply lower clinical dosage of the chemotherapeutics [8].

Photosensitizers and Dox are applied either separately as a co-treatment [19,20] or bound on the nanocarrier platform [9–16]. The enhanced efficiency of Dox included in nanoplateforms together with such photosensitizers as chlorin 6 [11,13,14], phthalocyanines [12,15,21], indocyanine green [22], merocyanine [9], methylene blue [10], and perfluorocarbon [16] was recently reported. The carbon nanostructure C<sub>60</sub> fullerene [23] (here abbreviated consistently C<sub>60</sub>) has attracted attention as a photosensitizer [1,24–27] due to its unique physicochemical behavior, high quantum yield of ROS production [28], photostability, low photobleaching [25] as well as predominant mitochondrial localization [29–32]. Pristine C<sub>60</sub> stable colloid solution with a negligible toxicity against normal cells [33,34] was explored for PDT [26,28,31,35–38]. A pronounced pro-apoptotic effect was detected in leukemic cells treated with pristine ≤20 μM C<sub>60</sub> and irradiated with UV-Vis light in the range of 320–600 nm [26,35–37,39,40]. A continuous intensification of ROS production and inhibition of glutathione-dependent antioxidant system testified a subsequent intense induction of oxidative stress [40]. As a result, store-operated Ca<sup>2+</sup> entry and cytochrome c release from mitochondria [37] induced Ca<sup>2+</sup>-dependent apoptosis of leukemic cells [39].


The combination of the C<sub>60</sub> pro-oxidant properties [26,31,36,37] and its drug delivery capability [24,41,42] makes this nanostructure attractive for cancer photodynamic chemotherapy (Figure 1). The purpose of this study was to assess the toxic effects of the non-covalent C<sub>60</sub>-Dox nanocomplex in combination with light irradiation (405 nm emission from high power single chip LED) on human leukemic CCRF-CEM cells. The nanocomplex was designed in two nanomolar ratios of C<sub>60</sub> to Dox (1:1 and 2:1) in order to investigate whether C<sub>60</sub>'s concentration affected Dox efficacy. Firstly, the intracellular localization of the nanocomplexes in leukemic cells was estimated with fluorescence microscopy following immunofluorescence staining. Then, the leukemic cells' viability was studied upon treatment with the nanocomplexes and 405 nm LED light irradiation. The anticancer pro-apoptotic potential of the combinative treatment was assessed by evaluation of intracellular ROS production, caspase 3/7 activity, ATP level, and phosphatidylserine translocation in the plasma membrane in leukemic cells.

## 2. Materials and Methods

### 2.1. Chemicals

Roswell Park Memorial Institute (RPMI) 1640 liquid medium, phosphate buffered saline (PBS), fetal bovine serum (FBS), penicillin/streptomycin, and L-glutamin were obtained from Biochrom (Berlin, Germany). Poly-D-lysine hydrobromide, triton X100, bovine serum albumin (BSA), 4',6-diamidin e-2'-phenylindole dihydrochloride (DAPI), glycerol, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), and Dox were obtained from Sigma-Aldrich Co. (St-Louis, MI, USA).

Paraformaldehyde, dimethylsulfoxide (DMSO), sodium chloride, acetonitrile, formic acid, and trypan blue from Carl Roth GmbH + Co. KG (Karlsruhe, Germany) were used.



**Figure 1.** C<sub>60</sub>-Dox nanocomplex for photodynamic chemotherapy: C<sub>60</sub> delivers Doxorubicin (Dox) into leukemic cells and intensifies its accumulation; following internalization, the drug is anticipated to be released from the nanocomplex; cancer cell is exposed to the double cytotoxic hit from both photoexcited C<sub>60</sub> (photodynamic therapy, PDT) and co-delivered Dox (improved chemotherapy, CT).

## 2.2. C<sub>60</sub> and C<sub>60</sub>-Dox Nanocomplex

The pristine C<sub>60</sub> aqueous colloid solution was prepared by C<sub>60</sub> transfer from toluene to water using continuous ultrasound sonication as described by Ritter et al. [43]. The obtained aqueous colloid solution of C<sub>60</sub> was characterized by 0.2 mM C<sub>60</sub> concentration, 99% purity, stability, and homogeneity; the average size of nanoparticles was 100 nm [43,44].

Dox was dissolved in water at 18.5 mM initial concentration.


C<sub>60</sub>-Dox nanocomplexes were created according to the following protocol. Briefly, Dox solution was mixed with C<sub>60</sub> colloid solution in 1:1 or 2:1 molar ratio of the components. The mixture was treated in the ultrasonic disperser for 30 min, stirred for 24 h at room temperature (RT) and centrifuged at 14,000 g for 15 min with the use of centrifuge filters Amicon Ultra-0.5 3 K (Sigma-Aldrich Co., St-Louis, MI, USA) for sample purification. The stability and concentration of the nanocomplexes were controlled with dynamic light scattering and high-performance liquid chromatography–mass spectrometry. The stability ( $\zeta$ -potential value) and size distribution (hydrodynamic diameter) of nanocomplexes as described in ref. [45] was systematically checked and shown to be practically unchanged after 6 months of storage in physiological saline solution. The concentration of C<sub>60</sub> and Dox in the stock solution of 1:1 nanocomplex was 100  $\mu$ M. The concentration of C<sub>60</sub> and Dox in the stock solution of 2:1 nanocomplex was 200  $\mu$ M (198.9  $\mu$ M) and 100  $\mu$ M, correspondingly.

Measuring the value of the translational diffusion coefficient as a function of C<sub>60</sub> concentration at constant Dox concentration was performed in ref. [46]. The diffusion curve displays very distinct changes at small C<sub>60</sub> concentrations and reaches a plateau for higher concentrations. It allows the

conclusion that the binding of Dox molecules mainly occurs with  $C_{60}$  nanoclusters in aqueous solution. Indirectly this conclusion is confirmed by the atomic force microscopy data [46]; most likely  $C_{60}$ -Dox nanocomplexes stabilized by the Dox-induced attenuation of electrostatic repulsion between  $C_{60}$ .

Finally, the maximum number of ligand molecules ( $N$ ) that can be bound with  $C_{60}$  in aqueous solution may be estimated independently with the help of proposed general up-scaled model [47] as well as molecular modeling. The following value was obtained for Dox:  $N = 3$  [48,49]. The calculated equilibrium hetero-complexation constant was equal to  $K_L \approx 60,000 \text{ M}^{-1}$  [47].

The content of 1:1 and 2:1  $C_{60}$ -Dox nanocomplexes after incubation in RPMI medium for 24 h was assessed to account for  $81.50\% \pm 5.03\%$  and  $83.83\% \pm 5.47\%$ , correspondingly, of the respective 0 h control (Figure 2). For this,  $C_{60}$ -Dox nanocomplexes were incubated in RPMI up to 24 h under the identical conditions adopted from cell-based experiments (450 nM, 2 mL, 37 °C). For sample purification from a released free drug, 500  $\mu\text{L}$  of each sample was filtered with the centrifugal filter devices Amicon Ultra-0.5 3 K (Sigma-Aldrich Co., St-Louis, MI, USA) according to the manufacturer's instructions: 14,000 g, 15 min for filtration; 1000 g, 2 min for recovery (reverse spin upside down in a new centrifuge tube). The content of the filter device was subjected to optical analysis.  $C_{60}$ -Dox nanocomplexes samples (50  $\mu\text{L}$ ) were placed into 384-well plate Sarstedt and fluorescence intensities were measured with a multimode microplate spectrometer Tecan Infinite M200 Pro (Tecan Infinite M200 Pro, Männedorf, Switzerland) at the following parameters:  $\lambda_{\text{ex}} = 470 \text{ nm}$ ,  $\lambda_{\text{em}} = 595 \text{ nm}$ , number of flashes per well—25, integration time—20  $\mu\text{s}$ . The obtained data were normalized with the RPMI control and expressed as percentage of the respective control sample, analyzed at 0 h.




**Figure 2.** Dox release from  $C_{60}$ -Dox nanocomplexes during 24 h of incubation in Roswell Park Memorial Institute (RPMI 1640) medium.

The used concentrations of the  $C_{60}$ -Dox nanocomplexes for cells treatment were 50, 150, and 450 nM, presented according to Dox concentrations in order to compare the effect of the nanocomplexes with the effect of the free drug.

### 2.3. LED Light Source for Photodynamic Therapy

For cell treatment in well plates a LED-based system was developed (Figure 3). The light source system consists of control and irradiation units. Taking our requirements from our recent experiments into account [31] we set up the irradiation unit with a high power single chip 405 nm LED VL400-EMITTER (Roithner Lasertechnik GmbH, Vienna, Austria) on a cylindrical heat sink (Figure 3a). The cascade of lens was designed to ensure high irradiation power density and even illumination over the well (Figure 3a). For the development of the optical cascade we applied an aspherical lens for reducing the divergence angle of the beam ( $D = 13.0 \text{ mm}$ ,  $h = 7.1 \text{ mm}$  from Cree Inc., Durham, North Carolina, USA), which allowed all light to be focused to a second spherical lens with  $35^\circ$  (50% int) angle ( $D = 16.4 \text{ mm}$ ,  $h = 5.0 \text{ mm}$  from Cree Inc., Durham, NC, USA) for increasing the radiation density. The diameter of the collimated beam was determined by the distance between the two lenses. The light

system provides the same power density at any point of irradiation. The maximum diameter of the beam was 35 mm and the minimum 25 mm with 130 mW power. The light fluence was used at either 5 or 10 J/cm<sup>2</sup> for comparison of cell treatment effect. The mounting carcass was built in SOLIDWorks from Dassault Systems (Vélizy-Villacoublay, France) (Figure 3b) and 3D-printed at Ultimaker 2+ (Utrecht, The Netherlands) (Figure 3c). The final light system was constructed with a metal turning and assembled at the Fotonika Plus Co. (Cherkasy, Ukraine) (Figure 3d).



**Figure 3.** LED light system: (a) scheme, that reveals its electrical part, LED, and optical system, (b) design of the mounting carcass in 3D Software SOLIDWorks (Dassault Systems, Vélizy-Villacoublay, France), (c) 3D printed plastic 1st model, (d) final metal model; scale bar corresponds to 10 mm.

#### 2.4. Cell Culture

The human cancer T-cell line CCRF-CEM (ACC 240) of leucosis origin was purchased from the Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures (Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, Germany).

Cells were maintained in 5 mL RPMI 1640 medium supplemented with 10% FBS, 1% Penicillin/Streptomycin and 2 mM Glutamine, using 25 cm<sup>2</sup> flasks at a 37 °C with 5% CO<sub>2</sub> in a humidified incubator Binder (Tuttligen, Germany). The number of the viable cells was counted with the use of Roche Cedex XS Analyzer (Basel, Switzerland) after staining with 0.1% trypan blue.

#### 2.5. Immunofluorescence Staining of C<sub>60</sub>

CCRF-CEM cells ( $2 \times 10^5/2$  mL) were seeded in 6-well plates (Sarstedt, Nümbrecht, Germany) on cover slips (Carl Roth, Karlsruhe, Germany), previously coated with poly-D-lysine and incubated for 24 h. Cells were treated with free Dox, C<sub>60</sub> or C<sub>60</sub>-Dox nanocomplexes in a 450 nM Dox equivalent concentration for a further 24 h. Then the cells were washed with PBS and fixed with 4% paraformaldehyde for 15 min at room temperature (RT) in the dark. After washing with PBS, the cells were permeabilized with 0.2% triton X100 for 10 min at RT and washed again with PBS. Blocking was performed using 10% BSA for 20 min followed by washing in PBS. The primary C<sub>60</sub>-mouse monoclonal IgG antibody bound to bovine thyroglobulin (dilution ratio of 1:30 in PBS/1.5% BSA, 1-10F-A8 Santa Cruz Biotechnology Inc., Santa Cruz, California, USA) was added to the medium and CCRF-CEM cells were incubated overnight at 4 °C in a humidified chamber. Then CCRF-CEM cells were incubated for 3 h at RT with a fluorescein isothiocyanate- (FITC) labeled polyclonal rabbit-anti-mouse IgG antibody (dilution ratio of 1:200 in PBS/1.5% BSA, F7506 Sigma-Aldrich Co., St-Louis, MI, USA). Slides were washed with PBS for 15 min three times. Coverslips were rinsed with dH<sub>2</sub>O, incubated for 2 h in the dark with the nucleus staining/antifade solution (0.6 μM DAPI, 90 mM p-phenylenediamine in glycerol/PBS) and sealed with slides.

## 2.6. Fluorescence Microscopy

Images of CCRF-CEM cells stained with DAPI, Dox, and FITC-labeled antibodies against  $C_{60}$ , were viewed with a fluorescence microscope Keyence BZ-9000 BIOREVO (Osaka, Japan). The microscope was equipped with blue ( $\lambda_{ex} = 377$  nm,  $\lambda_{em} = 447$  nm), green ( $\lambda_{ex} = 472$  nm,  $\lambda_{em} = 520$  nm), and red ( $\lambda_{ex} = 543$  nm,  $\lambda_{em} = 593$  nm) filters. The acquisition Keyence BZ-II Viewer Software (Osaka, Japan) was used. The merged images were processed with the Keyence BZ-II Analyzer Software (Osaka, Japan).

## 2.7. Photodynamic Therapy In Vitro and Cell Viability Assay

CCRF-CEM cells ( $10^4$ /well) were cultured in 96-well cell culture plates (Sarstedt, Nümbrecht, Germany) for 24 h. The cell culture medium was replaced by 1% FBS drug-contained medium. Cells were incubated in the presence of 50, 100, and 450 nM Dox or  $C_{60}$ -Dox nanocomplexes in Dox equivalent concentrations. After 24 h incubation cells were washed with PBS and irradiated with the developed 405 nm high power single chip LED light source ( $108.3$  mW/cm<sup>2</sup>, 5 or 10 J/cm<sup>2</sup>). PBS was replaced with the fresh medium immediately after irradiation. Control cells were incubated without any treatment or light irradiation. After 24 h incubation, cell viability was determined with MTT reduction assay [50]. 10  $\mu$ L of MTT solution (5 mg/mL in PBS) was added to each well and cells were incubated for 2 h at 37 °C. The culture medium was then replaced with 100  $\mu$ L of DMSO and in 15 min diformazan formation was determined by measuring the absorption at 570 nm with a microplate reader (Tecan Infinite M200 Pro, Männedorf, Switzerland). Curve fitting and calculation of the half-maximal inhibitory concentration (IC<sub>50</sub>) values were done using the specialized software GraphPad Prism 7 (GraphPad Software Inc., San Diego, CA, USA). Briefly, individual concentration-effect curves were generated by fitting the logarithm of the tested compound concentration versus the corresponding normalized percent of cell viability using nonlinear regression.

## 2.8. Intracellular Reactive Oxygen Species Generation

To determine ROS production 2,7-dichlorofluorescein diacetate (DCFH-DA, Sigma-Aldrich Co., St-Louis, Missouri, USA) was applied. A 5 mM stock solution of DCFH-DA was prepared in DMSO, stored at  $-20$  °C and diluted with PBS immediately before use. CCRF-CEM cells were seeded into 96-well plates ( $10^4$  cells/well) and incubated for 24 h. Then the medium was changed to that containing free 450 and 900 nM  $C_{60}$ , Dox or  $C_{60}$ -Dox nanocomplexes in 450 nM Dox-equivalent concentration for 24 h, irradiated (10 J/cm<sup>2</sup> 405 nm LED) as indicated above, incubated for 1 and 3 h and washed once with PBS. Five  $\mu$ M DCFH-DA was added and the fluorescence ( $\lambda_{ex} = 488$  nm,  $\lambda_{em} = 520$  nm) was recorded every 5 min over 50 min with the microplate reader Tecan Infinite M200 Pro (Männedorf, Switzerland). At 60 min of incubation, fluorescence images of cells were obtained with the fluorescence microscope Keyence BZ-9000 BIOREVO (Osaka, Japan), equipped with green filter ( $\lambda_{ex} = 472$  nm,  $\lambda_{em} = 520$  nm).

## 2.9. Intercellular ATP Content

CCRF-CEM cells were seeded into 96-well plates ( $10^4$  cells/well) and incubated for 24 h. Cells were treated with 450 and 900 nM free  $C_{60}$ , Dox or  $C_{60}$ -Dox nanocomplexes in 450 nM Dox-equivalent concentration for 24 h, irradiated with 405 nm, 10 J/cm<sup>2</sup> and transferred to 50  $\mu$ L glucose-free RPMI. At 3 h after light exposure the cell membrane integrity and cellular ATP level were estimated with the Promega Mitochondrial ToxGlo™ assay kit (Madison, WI, USA) according to the manufacturer's instructions. Briefly, plates were equilibrated to RT for 10 min and to each well the ATP Detection Reagent (50  $\mu$ L) was added containing luciferin, ATPase inhibitors and thermostable luciferase. After shaking at 600 rpm for 1 min the luminescence intensity was measured with the microplate reader Tecan Infinite M200 Pro (Männedorf, Switzerland).

### 2.10. Caspase 3/7 Activity

CCRF-CEM cells were seeded into 96-well plates ( $10^4$  cells/well) and incubated for 24 h. Cells were treated with 450 and 900 nM free  $C_{60}$ , Dox or  $C_{60}$ -Dox nanocomplexes in 450 nM Dox-equivalent concentration for 24 h and irradiated (405 nm,  $10 \text{ J/cm}^2$ ) as described above. Activity of caspases 3/7 was determined at 3 h after light exposure using the Promega Caspase-Glo<sup>®</sup> 3/7 Activity assay kit (Madison, WI, USA) according to the manufacturer's instructions. Briefly, plates were removed from the incubator and allowed to equilibrate to RT for 30 min. After that, an equal volume of Caspase-Glo 3/7 reagent containing luminogenic peptide substrate was added followed by gentle mixing with a plate shaker at 300 rpm for 1 min. The plate was then incubated at RT for 2 h. The luminescence intensity of the products of caspase 3/7 reaction was measured with the microplate reader Tecan Infinite M200 Pro (Männedorf, Switzerland).

### 2.11. Flow Cytometry Analysis

CCRF-CEM cells were seeded onto 6-well plates Sarstedt (Nümbrecht, Germany) at a cell density of  $2 \times 10^5$  cells/well in 2 mL of culture medium, incubated for 24 h, then treated with 450 and 900 nM free  $C_{60}$ , Dox or  $C_{60}$ -Dox nanocomplexes in 450 nM Dox-equivalent concentration for 24 h and irradiated (405 nm,  $10 \text{ J/cm}^2$ ) as described above. At 6 h of incubation period cells were harvested. Apoptosis was detected by Annexin V-FITC/propidium iodide (PI) apoptosis detection kit (eBioscience<sup>™</sup>, San Diego, CA, USA) according to the manufacturer's instructions. Briefly, cells were harvested and washed with Binding buffer. After addition of Annexin V-FITC cells were incubated for 15 min at RT in dark. Cells were washed with Binding buffer and at 10 min after PI addition were analyzed ( $\lambda_{\text{ex}} = 488 \text{ nm}$ ,  $\lambda_{\text{em}}$  (Annexin V-FITC) = 530/40 nm and  $\lambda_{\text{em}}$  (PI) = 692/40 nm) with a flow cytometer BD FACSJazz<sup>™</sup> (Franklin Lakes, New Jersey, USA). A minimum of  $2 \times 10^4$  cells per sample were acquired and analyzed with the BD FACST<sup>™</sup> software (Franklin Lakes, NJ, USA).

### 2.12. Statistics

All experiments were carried out with a minimum of four replicates. Data analysis was performed using the GraphPad Prism 7 Software (GraphPad Software Inc., San Diego, CA, USA). Paired Student's *t*-test was performed. Differences with *p*-values <0.01 were considered to be significant.

The combination index (CI), calculated according to the Chou–Talalay method [51] with the ComboSyn software (ComboSyn, Inc., Paramus, NJ, USA), was used to evaluate pharmacodynamic interactions between non-irradiated  $C_{60}$ -Dox nanocomplexes and photoexcitation of  $C_{60}$  in cells treated with  $C_{60}$ -Dox nanocomplexes and irradiated with 5 and  $10 \text{ J/cm}^2$  LED light. The following equation was used.

$$CI = \frac{(D)_1}{(D_{25})_1} + \frac{(D)_2}{(D_{25})_2} \quad (1)$$

where  $(D_{25})_1$  is the concentration of  $C_{60}$ -Dox that inhibited cell viability to 25%;  $(D_{25})_2$  is the concentration of free  $C_{60}$  that inhibited cell viability to 25% after photoexcitation;  $(D)_1$  and  $(D)_2$  are the concentrations of Dox and  $C_{60}$  in the  $C_{60}$ -Dox nanocomplexes which inhibited cell viability to 25% after  $C_{60}$  photoexcitation. A CI value of <1, =1 and >1 indicates a synergistic, additive and antagonistic interaction, respectively.

## 3. Results


### 3.1. Localization of $C_{60}$ and Dox in Cells Treated with $C_{60}$ -Dox Nanocomplexes

With the use of fluorescence-based techniques we could explain intracellular localization of  $C_{60}$  and Dox after CCRF-CEM cells' treatment with  $C_{60}$ -Dox nanocomplexes in the 1:1 and 2:1 nanomolar ratio. Since Dox possesses a strong absorption and fluorescence in the visible spectral region [52,53] the direct



tracking of this molecule is possible, whereas  $C_{60}$  monitoring requires additional immunofluorescence staining [30,31,54].

CCRF-CEM cells were incubated for 24 h with the agents under study and subjected to staining. The overlap of the Dox red signal with the nuclear marker DAPI blue signal confirmed the drug's nuclear localization (Figure 4). We detected substantially enhanced Dox level in cells treated with  $C_{60}$ -Dox nanocomplexes as compared with cells treated with the free Dox. Monitoring of the  $C_{60}$  distribution by the immunofluorescence green signal confirmed the intracellular accumulation of the nanostructure and pointed to its extranuclear localization. The  $C_{60}$  localization within mitochondria accounts for 72% of the whole cellular content as was shown before [31,32]. The observed intracellular allocation of Dox and  $C_{60}$  evidenced the effective intracellular Dox release from  $C_{60}$ -Dox nanocomplexes.




**Figure 4.** Fluorescence microscopy images of CCRF-CEM cells, stained with 4',6-diamidino-2-phenylindole dihydrochloride (DAPI, Blue), fluorescein isothiocyanate-based immunostaining for  $C_{60}$  (Green) and Dox (Red) after treatment with: 450 and 900 nM  $C_{60}$ , 450 nM Dox, 1:1 or 2:1  $C_{60}$ -Dox nanocomplex. The white scale bar corresponds to 20  $\mu\text{m}$ ; the yellow scale bar on images in the column "Merged x5" corresponds to 4  $\mu\text{m}$ .

Localization of the nanocomplex components in the different cell compartments strongly supports the possibility of an anticancer double hit strategy that is suggested to be realized by photoinduced pro-oxidant activity of  $C_{60}$  in mitochondria [31] and antiproliferative action of Dox in nuclei [2–4].

### 3.2. Cell Viability

The viability of cells incubated without any treatment was taken as 100% (control). No effect of  $C_{60}$  introduced alone on leukemic cell viability was detected, while the concentration-dependent toxic effect of free Dox was observed. After the treatment with 50, 150, and 450 nM Dox, cell viability was

decreased to  $81\% \pm 5\%$ ,  $70\% \pm 3\%$ , and  $49\% \pm 5\%$ , correspondingly (Figure 4). When cells were treated in the dark with the  $C_{60}$ -Dox nanocomplexes at Dox equivalent concentrations, further increase of the Dox toxicity by 10–20% (Figure 5) and the decrease of its  $IC_{50}$  (Table 1) were observed. These data denote  $C_{60}$ 's ability to facilitate intracellular Dox accumulation [55] and, therefore, potentiate its toxic effects.



**Figure 5.** Viability of CCRF-CEM cells: cells were treated with either  $C_{60}$  and Dox alone or  $C_{60}$ -Dox nanocomplexes in Dox equivalent concentrations and incubated in the dark or after light irradiation with 405 nm LED at 5 J/cm<sup>2</sup> (a) or 10 J/cm<sup>2</sup> (b) (\*  $p \leq 0.01$  in comparison with the respective dark control, \*\*  $p \leq 0.01$  in comparison with the photoexcited 1:1 nanocomplex).

**Table 1.**  $IC_{50}$  values for the free Dox and  $C_{60}$ -Dox nanocomplexes.

$IC_{50}$ , nM	Dark	5 J/cm <sup>2</sup>	10 J/cm <sup>2</sup>
Dox	$390 \pm 56$	$382 \pm 53$	$336 \pm 49$
1:1 $C_{60}$ -Dox	$135 \pm 29$	$86 \pm 19$	$44 \pm 7$ *
2:1 $C_{60}$ -Dox	$225 \pm 34$ **	$64 \pm 11$ *	$25 \pm 4$ **, **

\*  $p \leq 0.01$  in comparison with the respective dark control, \*\*  $p \leq 0.01$  in comparison with the 1:1 nanocomplex.

After combined treatment with C<sub>60</sub>-Dox nanocomplexes and light cells, viability as well as IC<sub>50</sub> values were considerably decreased compared with their dark toxic effects. The toxicity was dependent on the light fluence and C<sub>60</sub> concentration in the nanocomplex. Thus, the decrease of cell viability after the treatment with 1:1 C<sub>60</sub>-Dox nanocomplex and 5 J/cm<sup>2</sup> light was observed only when the nanocomplex was used at 450 nM C<sub>60</sub> equivalent concentration (Figure 5a). When the light fluence was increased up to 10 J/cm<sup>2</sup> the pronounced phototoxic effect became evident at all given concentrations of 1:1 C<sub>60</sub>-Dox nanocomplex (Figure 5b) and the IC<sub>50</sub> values appeared to be three and nine times lower as compared with the IC<sub>50</sub> for non-irradiated 1:1 C<sub>60</sub>-Dox nanocomplex and for the free Dox, correspondingly (Table 1).

The viability of cells treated with 2:1 C<sub>60</sub>-Dox nanocomplex and irradiated with 5 J/cm<sup>2</sup> light was decreased substantially in a concentration dependent manner. The most significant toxic effect was observed after the treatment with 2:1 C<sub>60</sub>-Dox nanocomplex and irradiation with 10 J/cm<sup>2</sup> light, when the IC<sub>50</sub> values was estimated to be nine and sixteen times lower as compared with the IC<sub>50</sub> for non-irradiated 2:1 C<sub>60</sub>-Dox nanocomplex and for the free Dox, correspondingly (Table 1). If comparing with the photodynamic effect from C<sub>60</sub> alone towards CCRF-CEM cells at the same conditions [31], we can conclude that the IC<sub>50</sub> of photoexcited 2:1 C<sub>60</sub>-Dox was 7 × 10<sup>3</sup>-fold decreased. No signs of appreciable viability were detected when cells were treated with 2:1 C<sub>60</sub>-Dox nanocomplex at 900 nM C<sub>60</sub> equivalent concentration and irradiated with 10 J/cm<sup>2</sup> light (Figure 5b).

To estimate the pharmacodynamics interactions of C<sub>60</sub>'s dual functionality, as a drug nanocarrier and as a photosensitizer in cells treated with nanocomplexes, we calculated the value of the combination index (Table 2). When cells were co-treated with C<sub>60</sub>-Dox nanocomplexes and LED light at 5 J/cm<sup>2</sup> fluence the CI values indicated a synergistic effect. While after co-treatment with 1:1 and 2:1 C<sub>60</sub>-Dox nanocomplexes and LED light at 10 J/cm<sup>2</sup> fluence, the CI value proved to have a strong and a very strong synergistic effect of the photoexcited nanocomplex components respectively in the applied bimodal strategy of cell treatment.

**Table 2.** Combination index of interaction between phototoxic effects of C<sub>60</sub> (PDT) and non-irradiated C<sub>60</sub>-Dox nanocomplexes (improved CT) <sup>1</sup>.


CI	5 J/cm <sup>2</sup>	10 J/cm <sup>2</sup>
1:1 C <sub>60</sub> -Dox	0.546 ± 0.037 (synergism)	0.130 ± 0.009 (strong synergism)
2:1 C <sub>60</sub> -Dox	0.316 ± 0.023 (synergism)	0.097 ± 0.002 (very strong synergism)

<sup>1</sup> This was measured after cells' co-treatment with C<sub>60</sub>-Dox nanocomplex and LED light. Classification of interaction was determined according to Chou [51].

Next the intracellular ROS generation, ATP level, and the markers of apoptotic death were assessed in CCRF-CEM cells after combined treatment with C<sub>60</sub>-Dox nanocomplexes and light.

### 3.3. Intracellular Reactive Oxygen Species Generation

The efficient and continuous intracellular ROS production is considered to be a critical step in realization of a photoexcited C<sub>60</sub> anticancer effect [31,36,40,56,57]. ROS generation in cells was evaluated with the use of the fluorescence dye DCFH-DA [58,59] at 1 and 3 h of incubation after light irradiation or in the dark. The minor increase of the fluorescence signal was detected during the incubation of the control untreated cells (Figure 6). No reliable changes in ROS generation in comparison with the control were observed when 450 or 900 nM C<sub>60</sub> was applied alone. Treatment with the free 450 nM Dox or C<sub>60</sub>-Dox nanocomplexes was followed by a slight increase of ROS generation at 1 h that was attenuated at 3 h (Figure 6a). When cells treated with the free C<sub>60</sub> or C<sub>60</sub>-Dox nanocomplexes were irradiated with 405 nm light at 10 J/cm<sup>2</sup> fluence the ROS production was intensified at both 1 and 3 h. In cells treated with 1:1 or 2:1 C<sub>60</sub>-Dox nanocomplex ROS levels at 3 h after irradiation exceeded the control level by 3.8 times and 5.0 times, correspondingly (Figure 6c).




**Figure 6.** Reactive oxygen species generation in CCRF-CEM cells treated with either Dox or C<sub>60</sub> alone or with C<sub>60</sub>-Dox nanocomplexes: the dynamics of ROS generation in cells at 1 and 3 h after the treatment in the dark (a) or irradiation with 10 J/cm<sup>2</sup> 405 nm LED (c); the fluorescence microscopy images of cells at 3 h after the treatment in dark (b) or light irradiation (d) and further 60 min incubation with 2,7-dichlorofluorescein diacetate (DCFH-DA); scale bar corresponds to 20 μm.

The analysis of the fluorescence microscopy images (Figure 6b,d) confirmed the obtained quantitative data on intense ROS production in cells irradiated after the treatment with C<sub>60</sub>-Dox nanocomplexes and supports oxidative stress as a precondition of mitochondrial dysfunction and intrinsic apoptotic pathway induction [17,60].

### 3.4. Intracellular ATP Content

Mitochondria play a leading role in apoptosis induction and progression and are an important subcellular target for many photosensitizing drugs [17,60]. Cytotoxic effects of photosensitizers are considered to be realized particularly through the mitochondrial oxidative damage [26,31,37]. Therefore, next we assessed whether the treatment of cells with C<sub>60</sub>-Dox nanocomplexes and light

affected ATP production as the main mitochondrial function. Neither free C<sub>60</sub> and Dox nor light irradiation alone had any effect on the ATP level in cells (Figure 7a).




**Figure 7.** ATP level (a) and caspase 3/7 activity (b) in CCRF-CEM cells at 3 h after treatment. Treatment was done with either free C<sub>60</sub> and Dox or C<sub>60</sub>-Dox nanocomplexes in the dark or after irradiation with 10 J/cm<sup>2</sup> 405 nm LED (\*  $p \leq 0.01$  in comparison with the respective dark control).

In cells treated with 1:1 and 2:1 C<sub>60</sub>-Dox nanocomplexes the ATP level was slightly decreased to  $84\% \pm 5\%$  and  $87\% \pm 3\%$  of the control, respectively. The appreciable drop in intracellular ATP level to  $30\% \pm 4\%$  and  $28\% \pm 3\%$  was observed after 10 J/cm<sup>2</sup> light irradiation of cells treated with 1:1 and 2:1 C<sub>60</sub>-Dox nanocomplexes respectively (Figure 7a), indicating inhibition of mitochondria function that could be attributed to impaired redox balance in cells.

### 3.5. Apoptosis Induction

Apoptotic program execution requires the coordinated activation of multiple subprograms including caspases cascade [5,61]. The executive caspase 3/7 activation and phosphatidylserine translocation into the outer layer of plasma membrane lipid bilayer were evaluated as the markers of apoptotic cell death. No effect of either free C<sub>60</sub> or Dox as well as of light irradiation alone on caspase 3/7 was observed following 3 h of cells incubation (Figure 7b). Irradiation of cells treated with 450 or 900 nM C<sub>60</sub> was followed by 1.6-fold and 1.9-fold increase of caspase 3/7 activity, respectively, while after irradiation of cells treated with 1:1 or 2:1 C<sub>60</sub>-Dox nanocomplexes 4.7-fold and 5.8-fold increase of caspase 3/7 activity respectively compared with control was observed (Figure 7b).

Finally, we checked the exposure of phosphatidylserine on the cell surface as an “eat me” signal, that induces phagocytic recognition and destruction of apoptotic cells [62]. To differentiate apoptotic cells fluorescence activated cell sorting (FACS) was used. On FACS histograms (Figure 8) the cell distribution at 6 h after the treatment with either free C<sub>60</sub> or Dox or C<sub>60</sub>-Dox nanocomplexes is presented according to the green and red fluorescence intensities of Annexin V-FITC and PI respectively. Viable (Annexin V-FITC negative, PI negative), early apoptotic (Annexin V-FITC positive, PI negative), late apoptotic (Annexin V-FITC positive, PI positive), and necrotic (Annexin V-FITC negative, PI positive) cells in their quantitative populations analyses are presented in Figure 8b. Neither treatment with C<sub>60</sub> nor 405 nm light irradiation alone had a significant effect on cell distribution profiles (FACS histograms are not shown). A slight increase in the number of early apoptotic cells was observed after treatments with free Dox, C<sub>60</sub>-Dox nanocomplexes or photoexcited C<sub>60</sub>. When cells treated with C<sub>60</sub>-Dox nanocomplexes were exposed to light a distribution-shift towards late apoptosis was observed. Thus, the content of Annexin V-FITC positive and PI positive cells in population of cells treated with photoexcited 1:1 and 2:1 C<sub>60</sub>-Dox nanocomplexes reached 93% and 96%, correspondingly (Figure 8).



**Figure 8.** Cell death differentiation in CCRF-CEM treated with either free C<sub>60</sub>, Dox or C<sub>60</sub>-Dox nanocomplexes: (a) flow cytometry histograms of CCRF-CEM cells stained with Annexin V-FITC/propidium iodide (PI) after treatment either with C<sub>60</sub>-Dox alone or in combination with 405 nm light (in each panel the lower left quadrant shows the content of viable, upper left quadrant—early apoptotic, upper right quadrant—late apoptotic, lower right quadrant—necrotic cells populations); (b) Quantitative analysis of cell population content, differentiated with double Annexin V-FITC/PI staining.

Taken together the data obtained confirmed the pro-apoptotic effect of combined treatment with C<sub>60</sub>-Dox nanocomplexes and 405 nm LED light irradiation on leukemic cells.

#### 4. Discussion

The nanoparticulation of anticancer drugs expands the scope of their chemical behavior and pharmacodynamics, as well as reducing efficient doses and unwanted side effects. Inclusion of the anticancer drug Dox into nanosized delivery systems prolongs its retention in the organism and favors its targeted accumulation in cancer cells [63,64].

In previous studies we exploited the ability of C<sub>60</sub> nanostructure's polyaromatic surface to absorb aromatic Dox molecules and synthesized non-covalent C<sub>60</sub>-Dox nanocomplexes. The physicochemical properties of the C<sub>60</sub>-Dox nanocomplexes studied with the different analytical methods confirmed their stability and biological applicability [45,52,59,65]. Complexation with C<sub>60</sub> increases the intracellular Dox level and improves Dox efficiency against human leukemic and colon cancer cells [49,55].

In the current study combination of the chemotherapeutic and photodynamic treatment strategies was explored on the basis of Dox nanocomplexes with C<sub>60</sub>. Nanocomplex of C<sub>60</sub> and Dox at molar ratios 1:1 and 2:1 and at Dox equivalent concentrations in a range  $\leq$ IC<sub>50</sub> (150–450 nM) were tested on human leukemic CCRF-CEM cells in combination with light irradiation.

With the use of indirect C<sub>60</sub> immunostaining we confirmed the intracellular accumulation of the carbon nanostructure in cells treated with free C<sub>60</sub> or C<sub>60</sub>-Dox nanocomplexes. When cells were treated with C<sub>60</sub>-Dox nanocomplexes, C<sub>60</sub> was found to be localized in the extranuclear space assumed to be in mitochondrial membranes as it was shown for C<sub>60</sub> at higher concentrations [31,32], whereas Dox was accumulated in the cell nucleus and in a higher concentration than after treatment with a free drug. These data are linked to the C<sub>60</sub> ability to promote passive diffusion and/or endocytosis/pinocytosis of the small molecules in cancer cells [66–68] and to bind P-glycoproteins [69], inhibiting Dox's pumping out from the cell. Comparably, graphene-based triple delivery nanosystems non-covalently loaded with Dox and phthalocyanine ensured higher cellular drug uptake and effective intracellular drug release [21].

The allocation of C<sub>60</sub> and Dox inside leukemic cells sets a background for the application of the "two swords" treatment strategy based on CT and PDT combination. Thus, nuclear Dox intercalated into DNA is supposed to block its transcription, replication, and repair [2–4], whereas photoexcited extranuclear C<sub>60</sub> can produce ROS and induce mitochondrial pathway of apoptosis [26,31,36,37,70].

The C<sub>60</sub> absorption spectrum has three intense bands in the ultraviolet region and a long broad tail up to the red region of the visible light [31,43]. The mutagenic potential of ultraviolet light makes its application unfavorable, therefore, we used irradiation with a 405 nm high power single chip light emitting diode at the fluence  $\leq$ 10 J/cm<sup>2</sup>, that was shown previously to be nontoxic and efficient for the photoexcitation of C<sub>60</sub> accumulated in CCRF-CEM cells [31].

In order to exploit C<sub>60</sub> photosensitizing activity a high-power a single chip light-emitting diode-based light source was constructed. The use of high-power single chip LEDs is expected to promote PDT application, since they have a higher portability and an extremely lower cost, compromising the efficiency of lasers [71,72]. The possibility to vary the evenly irradiated area is one of the main advantages of the developed system. It provided the same power density at any irradiation point, allowing for accurate calculation and selection of the irradiation dose. Consequently, the optical elements greatly increased the efficiency of using LED irradiation and helped to collimate irradiation in a narrower beam. To address a challenge of limited penetration depth of blue light in biological tissue, next steps could be aimed at additional skin optical clearing [73,74] or coupling of the LED light source with fiber optics for direct and precise light intra-tissue delivery.

It should be noted that we used C<sub>60</sub> in nanomolar concentrations in contrast to micromolar application in our previous studies [26,31,36,37] and by other authors [38,56,57,68,75,76]. Nanomolar C<sub>60</sub> was shown to have no dark toxicity and a slight pro-oxidant effect with 11.5% decrease of leukemic cell viability after 405 nm LED light irradiation at 10 J/cm<sup>2</sup> fluence.

When leukemic cells were treated with a 2:1 C<sub>60</sub>-Dox nanocomplex and irradiated with 10 J/cm<sup>2</sup> 405 nm LED light a 16-fold decrease of IC<sub>50</sub> was observed as compared with the IC<sub>50</sub> value for the free Dox (390 nM). Phototoxicity of 1:1 C<sub>60</sub>-Dox nanocomplex occurred to be less pronounced causing a

9-fold decrease of  $IC_{50}$  that can be attributed to the lower content of  $C_{60}$  as a photosensitizer. The value of the combination index, which was calculated to characterize the pharmacodynamic interactions, indicated a strong synergy between non-irradiated 2:1  $C_{60}$ -complexed Dox and photoexcited  $C_{60}$  with 10 J/cm<sup>2</sup> light. The high pro-apoptotic efficiency of the  $C_{60}$ -Dox nanocomplexes and light irradiation against CCRF-CEM cells were confirmed by significant increase of intracellular ROS, decreased ATP levels, caspase 3/7 activation, and transition of 90% of cells to the late apoptosis stage.

The data obtained demonstrate effective combination of chemotherapeutic and photodynamic cancer treatment strategies on the basis of the  $C_{60}$ -Dox nanosystem. To our knowledge we were the first to apply nanomolar concentrations of photosensitizer and drug in vitro for toxicity optimization in the frame of photodynamic chemotherapy with carbon nanomaterial. According to the recent literature data on carbon nanoparticle-mediated photodynamic chemotherapy the synergistic toxic effect of drug-loaded graphene was achieved with light irradiation of cervix, breast, and skin cancer cells treated with Dox-polylysine graphene-phthalocyanine [21] or lung cancer cells treated camptothecin-graphene oxide-hypocrellin A [77], both in the  $\mu$ M Dox concentrations. Moreover, dual functionality of  $C_{60}$ , as a drug nanocarrier and as a photosensitizer, enabled an easy and fast preparation of two-component  $C_{60}$ -Dox as compared to the mentioned three-component graphene-based nanosystems.

Chemo- and photodynamic anticancer agents have distinct intracellular targets and, therefore, induce different signaling pathways of cell injury. Earlier studies showed tumor-specific differential effects of agents under study. Thus, Dox attacked specifically fast proliferating cells [2–4], whereas  $C_{60}$  mainly targeted the redox state of the cell [24,25,28]. The synergistic effect of PDT and CT combination is attributed mainly to the further amplification of oxidative stress [8]. Intensive ROS production promotes apoptosis and assists drug delivery due to ROS-mediated lipid peroxidation of endosome membranes [8,16,17]. The efflux of the drug can be inhibited as well by ROS-mediated oxidation of the intracellular domain of the multidrug resistance P-glycoprotein [78–80]. ROS as signal intracellular messengers shift profiles of signaling pathways in treated cells. Hence, carbon nanoparticle induced ROS-mediated activation of the mitogen-activated protein kinase, that increased the vulnerability of lung cancer cells towards paclitaxel [81]. The cooperative enhancement interactions between mechanisms of chemo- and photodynamic therapies contribute to the obtained synergistic effect (namely “1 + 1 > 2”).

**Author Contributions:** The presented work was carried out in collaboration between all authors. Conceptualization, A.G., O.M., Y.P., and M.F.; Formal analysis, A.G.; Funding acquisition, A.G., T.Y.O., T.D., and M.F.; Investigation, A.G.; Methodology, A.G., O.C., S.G., S.P., Y.P., and U.R.; Project administration, A.G., T.D., and M.F.; Resources, M.F.; Supervision, O.M., T.Y.O., T.D., and M.F.; Validation, A.G., S.G., and O.C.; Visualization, A.G.; Writing—original draft, A.G., O.M., and M.F.; Writing—review and editing, all authors.

**Funding:** We thank the German Academic Exchange Service (DAAD) for their support (scholarship for AG 57129429). T.D. acknowledges support by BMBF (Remis-3R, FKZ 031L0129B). O.C. and T.Y.O. were supported in part by the National Natural Science Foundation of China (grant number 61875135) and the Shenzhen Basic Research Project (grant number JCYJ20170818090620324).

**Acknowledgments:** The authors are very grateful to Karsten Lange (SLT Sensor- und Lasertechnik GmbH, Wildau) for the measurements of LED light source fluence, Benjamin Girke (Oculyze GmbH, Wildau) for 3D printing, and Hryhorii Mykhailov (Antonov State Company, Kyiv) for the help with 3D modeling in SOLIDWorks.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Chabner, B.A.; Roberts, T.G. Timeline: Chemotherapy and the war on cancer. *Nat. Rev. Cancer* **2005**, *5*, 65–72. [[CrossRef](#)] [[PubMed](#)]
2. Tacar, O.; Sriamornsak, P.; Dass, C.R. Doxorubicin: An update on anticancer molecular action, toxicity and novel drug delivery systems. *J. Pharm. Pharmacol.* **2013**, *65*, 157–170. [[CrossRef](#)] [[PubMed](#)]
3. Thorn, C.F.; Oshiro, C.; Marsh, S.; Hernandez-Boussard, T.; McLeod, H.; Klein, T.E.; Altman, R.B. Doxorubicin pathways: Pharmacodynamics and adverse effects. *Pharmacogenet. Genom.* **2011**, *21*, 440–446. [[CrossRef](#)] [[PubMed](#)]



4. Kizek, R.; Adam, V.; Hrabeta, J.; Eckschlager, T.; Smutny, S.; Burda, J.V.; Frei, E.; Stiborova, M. Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances. *Pharmacol. Ther.* **2012**, *133*, 26–39. [[CrossRef](#)] [[PubMed](#)]
5. Finn, N.A.; Findley, H.W.; Kemp, M.L. A switching mechanism in doxorubicin bioactivation can be exploited to control doxorubicin toxicity. *PLoS Comput. Biol.* **2011**, *7*, e1002151. [[CrossRef](#)] [[PubMed](#)]
6. Jung, K.; Reszka, R. Mitochondria as subcellular targets for clinically useful anthracyclines. *Adv. Drug Deliv. Rev.* **2001**, *49*, 87–105. [[CrossRef](#)]
7. Li, L.; Xie, J.; Zhang, X.; Chen, J.; Luo, Y.; Zhang, L.; Luo, R. Retrospective study of photodynamic therapy vs. photodynamic therapy combined with chemotherapy and chemotherapy alone on advanced esophageal cancer. *Photodiagnosis Photodyn. Ther.* **2010**, *7*, 139–143. [[CrossRef](#)] [[PubMed](#)]
8. Fan, W.; Yung, B.; Huang, P.; Chen, X. Nanotechnology for Multimodal Synergistic Cancer Therapy. *Chem. Rev.* **2017**, *117*, 13566–13638. [[CrossRef](#)]
9. Wang, X.; Meng, G.; Zhang, S.; Liu, X. A Reactive  $^1\text{O}_2$ -Responsive Combined Treatment System of Photodynamic and Chemotherapy for Cancer. *Sci. Rep.* **2016**, *6*, 29911. [[CrossRef](#)]
10. Khaliq, N.U.; Park, D.Y.; Lee, H.J.; Oh, K.S.; Seo, J.H.; Kim, S.Y.; Hwang, C.S.; Lim, T.-H.; Yuk, S.H. Pluronic/Heparin Nanoparticles for Chemo-Photodynamic Combination Cancer Therapy through Photoinduced Caspase-3 Activation. *ACS Appl. Nano Mater.* **2018**, *1*, 2943–2952. [[CrossRef](#)]
11. Sun, C.-Y.; Cao, Z.; Zhang, X.-J.; Sun, R.; Yu, C.-S.; Yang, X. Cascade-amplifying synergistic effects of chemo-photodynamic therapy using ROS-responsive polymeric nanocarriers. *Theranostics* **2018**, *8*, 2939–2953. [[CrossRef](#)] [[PubMed](#)]
12. Ke, M.-R.; Chen, S.-F.; Peng, X.-H.; Zheng, Q.-F.; Zheng, B.-Y.; Yeh, C.-K.; Huang, J.-D. A tumor-targeted activatable phthalocyanine-tetrapeptide-doxorubicin conjugate for synergistic chemo-photodynamic therapy. *Eur. J. Med. Chem.* **2017**, *127*, 200–209. [[CrossRef](#)] [[PubMed](#)]
13. Peng, C.-L.; Lai, P.-S.; Lin, F.-H.; Yueh-Hsiu Wu, S.; Shieh, M.-J. Dual chemotherapy and photodynamic therapy in an HT-29 human colon cancer xenograft model using SN-38-loaded chlorin-core star block copolymer micelles. *Biomaterials* **2009**, *30*, 3614–3625. [[CrossRef](#)] [[PubMed](#)]
14. Zhang, Y.; Huang, F.; Ren, C.; Yang, L.; Liu, J.; Cheng, Z.; Chu, L.; Liu, J. Targeted Chemo-Photodynamic Combination Platform Based on the DOX Prodrug Nanoparticles for Enhanced Cancer Therapy. *ACS Appl. Mater. Interfaces* **2017**, *9*, 13016–13028. [[CrossRef](#)] [[PubMed](#)]
15. Candido, N.M.; de Melo, M.T.; Franchi, L.P.; Primo, F.L.; Tedesco, A.C.; Rahal, P.; Calmon, M.F. Combining Photodynamic Therapy and Chemotherapy: Improving Breast Cancer Treatment with Nanotechnology. *J. Biomed. Nanotechnol.* **2018**, *14*, 994–1008. [[CrossRef](#)] [[PubMed](#)]
16. Lee, Y.-H.; Ma, Y.-T. Synthesis, characterization, and biological verification of anti-HER2 indocyanine green-doxorubicin-loaded polyethyleneimine-coated perfluorocarbon double nanoemulsions for targeted photochemotherapy of breast cancer cells. *J. Nanobiotechnol.* **2017**, *15*, 41. [[CrossRef](#)]
17. Ribeiro, J.N.; da Silva, A.R.; Jorge, R.A. Involvement of mitochondria in apoptosis of cancer cells induced by photodynamic therapy. *J. Bras. Patol. Med. Lab.* **2004**, *40*, 383–390. [[CrossRef](#)]
18. Agostinis, P.; Berg, K.; Cengel, K.A.; Foster, T.H.; Girotti, A.W.; Gollnick, S.O.; Hahn, S.M.; Hamblin, M.R.; Juzeniene, A.; Kessel, D.; et al. Photodynamic Therapy of Cancer: An Update. *CA A Cancer J. Clin.* **2011**, *61*, 250–281. [[CrossRef](#)]
19. Lu, D.Y.; Chen, E.H.; Ding, J.; Xu, B.; Lu, T. R Anticancer drug combinations, a big momentum is needed. *J. Postgenom. Drug Biomark. Dev.* **2015**, *5*, e139. [[CrossRef](#)]
20. Anigo, E.C.; George, B.P.A.; Abrahamse, H. In vitro combined effect of Doxorubicin and sulfonated zinc Phthalocyanine-mediated photodynamic therapy on MCF-7 breast cancer cells. *Tumor Biol.* **2017**, *39*, 1010428317727278. [[CrossRef](#)]
21. Wu, C.; He, Q.; Zhu, A.; Li, D.; Xu, M.; Yang, H.; Liu, Y. Synergistic anticancer activity of photo- and chemoresponsive nanoformulation based on polylysine-functionalized graphene. *ACS Appl. Mater. Interfaces* **2014**, *6*, 21615–21623. [[CrossRef](#)] [[PubMed](#)]
22. Li, X.; Zhao, X.; Pardhi, D.; Wu, Q.; Zheng, Y.; Zhu, H.; Mao, Z. Folic acid modified cell membrane capsules encapsulating doxorubicin and indocyanine green for highly effective combinational therapy in vivo. *Acta Biomater.* **2018**, *74*, 374–384. [[CrossRef](#)] [[PubMed](#)]
23. Kroto, H.W.; Heath, J.R.; O'Brien, S.C.; Curl, R.F.; Smalley, R.E.  $\text{C}_{60}$ : Buckminsterfullerene. *Nature* **1985**, *318*, 162–163. [[CrossRef](#)]

24. Goodarzi, S.; Da Ros, T.; Conde, J.; Sefat, F.; Mozafari, M. Fullerene: Biomedical engineers get to revisit an old friend. *Mater. Today* **2017**, *20*, 460–480. [[CrossRef](#)]
25. Sharma, S.K.; Chiang, L.Y.; Hamblin, M.R. Photodynamic therapy with fullerenes in vivo: Reality or a dream? *Nanomedicine* **2011**, *6*, 1813–1825. [[CrossRef](#)] [[PubMed](#)]
26. Scharff, P.; Ritter, U.; Matyshevska, O.P.; Prylutska, S.V.; Grynyuk, I.I.; Golub, A.A.; Prylutsky, Y.I.; Burlaka, A.P. Therapeutic reactive oxygen generation. *Tumori J.* **2008**, *94*, 278–283. [[CrossRef](#)]
27. Tabata, Y.; Murakami, Y.; Ikada, Y. Photodynamic effect of polyethylene glycol-modified fullerene on tumor. *Jpn. J. Cancer Res.* **1997**, *88*, 1108–1116. [[CrossRef](#)]
28. Orlova, M. Perspectives of Fullerene Derivatives in PDT and Radiotherapy of Cancers. *Br. J. Med. Med Res.* **2013**, *3*, 1731–1756. [[CrossRef](#)]
29. Foley, S.; Crowley, C.; Smaih, M.; Bonfils, C.; Erlanger, B.F.; Seta, P.; Larroque, C. Cellular localisation of a water-soluble fullerene derivative. *Biochem. Biophys. Res. Commun.* **2002**, *294*, 116–119. [[CrossRef](#)]
30. Chirico, F.; Fumelli, C.; Marconi, A.; Tinari, A.; Straface, E.; Malorni, W.; Pellicciari, R.; Pincelli, C. Carboxyfullerenes localize within mitochondria and prevent the UVB-induced intrinsic apoptotic pathway. *Exp. Dermatol.* **2007**, *16*, 429–436. [[CrossRef](#)]
31. Grebinyk, A.; Grebinyk, S.; Prylutska, S.; Ritter, U.; Matyshevska, O.; Dandekar, T.; Frohme, M. C<sub>60</sub> fullerene accumulation in human leukemic cells and perspectives of LED-mediated photodynamic therapy. *Free Radic. Biol. Med.* **2018**, *124*, 319–327. [[CrossRef](#)] [[PubMed](#)]
32. Grebinyk, A.; Grebinyk, S.; Prylutska, S.; Ritter, U.; Matyshevska, O.; Dandekar, T.; Frohme, M. HPLC-ESI-MS method for C<sub>60</sub> fullerene mitochondrial content quantification. *Data Brief* **2018**, *19*, 2047–2052. [[CrossRef](#)] [[PubMed](#)]
33. Prylutska, S.V.; Grynyuk, I.I.; Grebinyk, S.M.; Matyshevska, O.P.; Prylutsky, Y.I.; Ritter, U.; Siegmund, C.; Scharff, P. Comparative study of biological action of fullerenes C<sub>60</sub> and carbon nanotubes in thymus cells. *Materialwissenschaft und Werkstofftechnik* **2009**, *40*, 238–241. [[CrossRef](#)]
34. Prylutska, S.V.; Matyshevska, O.P.; Golub, A.A.; Prylutsky, Y.I.; Potebnya, G.P.; Ritter, U.; Scharff, P. Study of C<sub>60</sub> fullerenes and C<sub>60</sub>-containing composites cytotoxicity in vitro. *Mater. Sci. Eng. C* **2007**, *27*, 1121–1124. [[CrossRef](#)]
35. Burlaka, A.P.; Sidorik, Y.P.; Prylutska, S.V.; Matyshevska, O.P.; Golub, O.A.; Prylutsky, Y.I.; Scharff, P. Catalytic system of the reactive oxygen species on the C<sub>60</sub> fullerene basis. *Exp. Oncol.* **2004**, *26*, 326–327. [[PubMed](#)]
36. Prylutska, S.V.; Grynyuk, I.I.; Palyvoda, K.O.; Matyshevska, O.P. Photoinduced cytotoxic effect of fullerenes C<sub>60</sub> on transformed T-lymphocytes. *Exp. Oncol.* **2010**, *32*, 29–32.
37. Grebinyk, S.M.; Palyvoda, K.O.; Prylutska, S.V.; Grynyuk, I.I.; Samoilenko, A.A.; Drobot, L.B.; Matyshevska, O.P. Photoactivated fullerene C<sub>60</sub> induces store-operated Ca<sup>2+</sup> entry and cytochrome c release in Jurkat cells. *Ukr Biokhim Zh (1999)* **2012**, *84*, 58–63.
38. Mroz, P.; Tegos, G.P.; Gali, H.; Wharton, T.; Sarna, T.; Hamblin, M.R. Photodynamic therapy with fullerenes. *Photochem. Photobiol. Sci.* **2007**, *6*, 1139–1149. [[CrossRef](#)]
39. Palyvoda, K.O.; Grynyuk, I.I.; Prylutska, S.V.; Samoilenko, A.A.; Drobot, L.B.; Matyshevska, O.P. Apoptosis photoinduction by C<sub>60</sub> fullerene in human leukemic T cells. *Ukr Biokhim Zh (1999)* **2010**, *82*, 121–127.
40. Grynyuk, I.; Grebinyk, S.; Prylutska, S.; Mykhailova, A.; Franskevich, D.; Matyshevska, O.; Schütze, C.; Ritter, U. Photoexcited fullerene C<sub>60</sub> disturbs prooxidant-antioxidant balance in leukemic L1210 cells. *Materialwissenschaft und Werkstofftechnik* **2013**, *44*, 139–143. [[CrossRef](#)]
41. Montellano, A.; Da Ros, T.; Bianco, A.; Prato, M. Fullerene C<sub>60</sub> as a multifunctional system for drug and gene delivery. *Nanoscale* **2011**, *3*, 4035–4041. [[CrossRef](#)] [[PubMed](#)]
42. Kumar, M.; Raza, K. C<sub>60</sub>-fullerenes as Drug Delivery Carriers for Anticancer Agents: Promises and Hurdles. *Pharm. Nanotechnol.* **2017**, *5*, 169–179. [[CrossRef](#)] [[PubMed](#)]
43. Ritter, U.; Prylutsky, Y.I.; Evstigneev, M.P.; Davidenko, N.A.; Cherepanov, V.V.; Senenko, A.I.; Marchenko, O.A.; Naumovets, A.G. Structural Features of Highly Stable Reproducible C<sub>60</sub> Fullerene Aqueous Colloid Solution Probed by Various Techniques. *Fuller. Nanotub. Carbon Nanostruct.* **2015**, *23*, 530–534. [[CrossRef](#)]
44. Prylutsky, Y.I.; Buchelnikov, A.S.; Voronin, D.P.; Kostjukov, V.V.; Ritter, U.; Parkinson, J.A.; Evstigneev, M.P. C<sub>60</sub> fullerene aggregation in aqueous solution. *Phys. Chem. Chem. Phys.* **2013**, *15*, 9351–9360. [[CrossRef](#)]

45. Prylutskyy, Y.I.; Evstigneev, M.P.; Cherepanov, V.V.; Kyzyma, O.A.; Bulavin, L.A.; Davidenko, N.A.; Scharff, P. Structural organization of C<sub>60</sub> fullerene, doxorubicin, and their complex in physiological solution as promising antitumor agents. *J. Nanopart. Res.* **2015**, *17*, 45. [[CrossRef](#)]
46. Prylutskyy, Y.I.; Evstigneev, M.P.; Pashkova, I.S.; Wyrzykowski, D.; Woziwodzka, A.; Gołuński, G.; Piosik, J.; Cherepanov, V.V.; Ritter, U. Characterization of C<sub>60</sub> fullerene complexation with antibiotic doxorubicin. *Phys. Chem. Chem. Phys.* **2014**, *16*, 23164–23172. [[CrossRef](#)]
47. Mosunov, A.; Evstigneev, V.; Buchelnikov, A.; Salo, V.; Prylutskyy, Y.; Evstigneev, M. General up-scaled model of ligand binding with C<sub>60</sub> fullerene clusters in aqueous solution. *Chem. Phys. Lett.* **2019**, *721*, 22–26. [[CrossRef](#)]
48. Evstigneev, M.P.; Buchelnikov, A.S.; Voronin, D.P.; Rubin, Y.V.; Belous, L.F.; Prylutskyy, Y.I.; Ritter, U. Complexation of C<sub>60</sub> fullerene with aromatic drugs. *ChemPhysChem* **2013**, *14*, 568–578. [[CrossRef](#)]
49. Panchuk, R.R.; Prylutska, S.V.; Chumakl, V.V.; Skorokhyd, N.R.; Lehka, L.V.; Evstigneev, M.P.; Prylutskyy, Y.I.; Berger, W.; Heffeter, P.; Scharff, P.; et al. Application of C<sub>60</sub> Fullerene-Doxorubicin Complex for Tumor Cell Treatment In Vitro and In Vivo. *J. Biomed. Nanotechnol.* **2015**, *11*, 1139–1152. [[CrossRef](#)]
50. Carmichael, J.; DeGraff, W.G.; Gazdar, A.F.; Minna, J.D.; Mitchell, J.B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing. *Cancer Res.* **1987**, *47*, 936–942.
51. Chou, T.-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. *Pharmacol. Rev.* **2006**, *58*, 621–681. [[CrossRef](#)] [[PubMed](#)]
52. Motlagh, N.S.H.; Parvin, P.; Ghasemi, F.; Atyabi, F. Fluorescence properties of several chemotherapy drugs: Doxorubicin, paclitaxel and bleomycin. *Biomed. Opt. Express* **2016**, *7*, 2400–2406. [[CrossRef](#)] [[PubMed](#)]
53. Changenet-Barret, P.; Gustavsson, T.; Markovitsi, D.; Manet, I.; Monti, S. Unravelling molecular mechanisms in the fluorescence spectra of doxorubicin in aqueous solution by femtosecond fluorescence spectroscopy. *Phys. Chem. Chem. Phys.* **2013**, *15*, 2937–2944. [[CrossRef](#)] [[PubMed](#)]
54. Ali, S.S.; Hardt, J.I.; Quick, K.L.; Kim-Han, J.S.; Erlanger, B.F.; Huang, T.-T.; Epstein, C.J.; Dugan, L.L. A biologically effective fullerene (C<sub>60</sub>) derivative with superoxide dismutase mimetic properties. *Free Radic. Biol. Med.* **2004**, *37*, 1191–1202. [[CrossRef](#)] [[PubMed](#)]
55. Grebinyk, A.; Prylutska, S.; Grebinyk, S.; Prylutskyy, Y.; Ritter, U.; Matyshevska, O.; Dandekar, T.; Frohme, M. Complexation with C<sub>60</sub> Fullerene Increases Doxorubicin Efficiency against Leukemic Cells In Vitro. *Nanoscale Res. Lett.* **2019**, *14*, 61. [[CrossRef](#)]
56. Yu, C.; Avci, P.; Canteenwala, T.; Chiang, L.Y.; Chen, B.J.; Hamblin, M.R. Photodynamic Therapy with Hexa(sulfo-*n*-butyl)[60]Fullerene Against Sarcoma In Vitro and In Vivo. *J. Nanosci. Nanotechnol.* **2016**, *16*, 171–181. [[CrossRef](#)]
57. Liao, F.; Saitoh, Y.; Miwa, N. Anticancer Effects of Fullerene [C<sub>60</sub>] Included in Polyethylene Glycol Combined With Visible Light Irradiation Through ROS Generation and DNA Fragmentation on Fibrosarcoma Cells With Scarce Cytotoxicity to Normal Fibroblasts. *Oncol. Res. Featur. Preclin. Clin. Cancer Ther.* **2011**, *19*, 203–216. [[CrossRef](#)]
58. Eruslanov, E.; Kusmartsev, S. Identification of ROS using oxidized DCFDA and flow-cytometry. *Methods Mol. Biol.* **2010**, *594*, 57–72. [[CrossRef](#)]
59. Myhre, O.; Andersen, J.M.; Aarnes, H.; Fonnum, F. Evaluation of the probes 2',7'-dichlorofluorescein diacetate, luminol, and lucigenin as indicators of reactive species formation. *Biochem. Pharmacol.* **2003**, *65*, 1575–1582. [[CrossRef](#)]
60. Castano, A.P.; Demidova, T.N.; Hamblin, M.R. Mechanisms in photodynamic therapy: Part one-photosensitizers, photochemistry and cellular localization. *Photodiagnosis Photodyn. Ther.* **2004**, *1*, 279–293. [[CrossRef](#)]
61. Fesik, S.W. Promoting apoptosis as a strategy for cancer drug discovery. *Nat. Rev. Cancer* **2005**, *5*, 876–885. [[CrossRef](#)] [[PubMed](#)]
62. Suzuki, J.; Denning, D.P.; Imanishi, E.; Horvitz, H.R.; Nagata, S. Xk-related protein 8 and CED-8 promote phosphatidylserine exposure in apoptotic cells. *Science* **2013**, *341*, 403–406. [[CrossRef](#)] [[PubMed](#)]
63. Fojtu, M.; Gumulec, J.; Stracina, T.; Raudenska, M.; Skotakova, A.; Vaculovicova, M.; Adam, V.; Babula, P.; Novakova, M.; Masarik, M. Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review. *Curr. Drug Metab.* **2017**, *18*, 237–263. [[CrossRef](#)] [[PubMed](#)]
64. Patil, R.R.; Guhagarkar, S.A.; Devarajan, P.V. Engineered nanocarriers of doxorubicin: A current update. *Crit. Rev. Ther. Drug Carr. Syst.* **2008**, *25*, 1–61. [[CrossRef](#)]

65. Bulavin, L.A.; Prylutsky, Y.; Kyzyma, O.; Evstigneev, M.; Ritter, U.; Scharff, P. Self-Organization of Pristine C<sub>60</sub> Fullerene and its Complexes with Chemotherapy Drugs in Aqueous Solution as Promising Anticancer Agents. In *Modern Problems of Molecular Physics*; Bulavin, L.A., Chalyi, A.V., Eds.; Springer International Publishing: Berlin/Heidelberg, Germany, 2018; Volume 197, pp. 3–22.
66. Russ, K.A.; Elvati, P.; Parsonage, T.L.; Dews, A.; Jarvis, J.A.; Ray, M.; Schneider, B.; Smith, P.J.S.; Williamson, P.T.F.; Violi, A.; et al. C<sub>60</sub> fullerene localization and membrane interactions in RAW 264.7 immortalized mouse macrophages. *Nanoscale* **2016**, *8*, 4134–4144. [[CrossRef](#)] [[PubMed](#)]
67. Zhang, L.W.; Yang, J.; Barron, A.R.; Monteiro-Riviere, N.A. Endocytic mechanisms and toxicity of a functionalized fullerene in human cells. *Toxicol. Lett.* **2009**, *191*, 149–157. [[CrossRef](#)]
68. Asada, R.; Liao, F.; Saitoh, Y.; Miwa, N. Photodynamic anti-cancer effects of fullerene [C60]–PEG complex on fibrosarcomas preferentially over normal fibroblasts in terms of fullerene uptake and cytotoxicity. *Mol. Cell. Biochem.* **2014**, *390*, 175–184. [[CrossRef](#)]
69. Prylutska, S.; Panchuk, R.; Gołuński, G.; Skivka, L.; Prylutsky, Y.; Hurmach, V.; Skorohyd, N.; Borowik, A.; Woziwodzka, A.; Piosik, J.; et al. C<sub>60</sub> fullerene enhances cisplatin anticancer activity and overcomes tumor cell drug resistance. *Nano Res.* **2017**, *10*, 652–671. [[CrossRef](#)]
70. Franskevych, D.; Palyvoda, K.; Petukhov, D.; Prylutska, S.; Grynyuk, I.; Schuetze, C.; Drobot, L.; Matyshevska, O.; Ritter, U. Fullerene C<sub>60</sub> Penetration into Leukemic Cells and Its Photoinduced Cytotoxic Effects. *Nanoscale Res. Lett.* **2017**, *12*, 40. [[CrossRef](#)]
71. Yu, C.-H.; Lin, H.-P.; Chen, H.-M.; Yang, H.; Wang, Y.-P.; Chiang, C.-P. Comparison of clinical outcomes of oral erythroleukoplakia treated with photodynamic therapy using either light-emitting diode or laser light. *Lasers Surg. Med.* **2009**, *41*, 628–633. [[CrossRef](#)]
72. Erkiert-Polguj, A.; Halbina, A.; Polak-Pacholczyk, I.; Rotsztejn, H. Light-emitting diodes in photodynamic therapy in non-melanoma skin cancers—own observations and literature review. *J. Cosmet. Laser Ther.* **2016**, *18*, 105–110. [[CrossRef](#)] [[PubMed](#)]
73. Hirshburg, J.; Choi, B.; Nelson, J.S.; Yeh, A.T. Correlation between collagen solubility and skin optical clearing using sugars. *Lasers Surg. Med.* **2007**, *39*, 140–144. [[CrossRef](#)] [[PubMed](#)]
74. Zhu, D.; Larin, K.V.; Luo, Q.; Tuchin, V.V. Recent progress in tissue optical clearing. *Laser Photon. Rev.* **2013**, *7*, 732–757. [[CrossRef](#)] [[PubMed](#)]
75. Lee, D.J.; Ahn, Y.S.; Youn, Y.S.; Lee, E.S. Poly(ethylene glycol)-crosslinked fullerenes for high efficient phototherapy: Multimeric Fullerenes. *Polym. Adv. Technol.* **2013**, *24*, 220–227. [[CrossRef](#)]
76. Yin, R.; Wang, M.; Huang, Y.-Y.; Huang, H.-C.; Avci, P.; Chiang, L.Y.; Hamblin, M.R. Photodynamic therapy with decacationic [60] fullerene monoadducts: Effect of a light absorbing electron-donor antenna and micellar formulation. *Nanomedicine* **2014**, *10*, 795–808. [[CrossRef](#)]
77. Zhou, L.; Zhou, L.; Wei, S.; Ge, X.; Zhou, J.; Jiang, H.; Li, F.; Shen, J. Combination of chemotherapy and photodynamic therapy using graphene oxide as drug delivery system. *J. Photochem. Photobiol. B Biol.* **2014**, *135*, 7–16. [[CrossRef](#)]
78. Khadair, A.; Chen, D.; Patil, Y.; Ma, L.; Dou, Q.P.; Shekhar, M.P.V.; Panyam, J. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance. *J. Control Release* **2010**, *141*, 137–144. [[CrossRef](#)]
79. Kalluru, P.; Vankayala, R.; Chiang, C.-S.; Hwang, K.C. Unprecedented “All-in-One” Lanthanide-Doped Mesoporous Silica Frameworks for Fluorescence/MR Imaging and Combination of NIR Light Triggered Chemo-Photodynamic Therapy of Tumors. *Adv. Funct. Mater.* **2016**, *26*, 7908–7920. [[CrossRef](#)]
80. Chen, Q.; Wang, X.; Wang, C.; Feng, L.; Li, Y.; Liu, Z. Drug-Induced Self-Assembly of Modified Albumins as Nano-theranostics for Tumor-Targeted Combination Therapy. *ACS Nano* **2015**, *9*, 5223–5233. [[CrossRef](#)]
81. Arya, N.; Arora, A.; Vasu, K.S.; Sood, A.K.; Katti, D.S. Combination of single walled carbon nanotubes/graphene oxide with paclitaxel: A reactive oxygen species mediated synergism for treatment of lung cancer. *Nanoscale* **2013**, *5*, 2818–2829. [[CrossRef](#)]

